Literature DB >> 28083669

Use of antipsychotics increases the risk of fracture: a systematic review and meta-analysis.

S-H Lee1,2, W-T Hsu3, C-C Lai4, A Esmaily-Fard5, Y-W Tsai6, C-C Chiu1, J Wang7, S-S Chang8,9, C C Lee10.   

Abstract

Our systematic review and meta-analysis of observational studies indicated that the use of antipsychotics was associated with a nearly 1.5-fold increase in the risk of fracture. First-generation antipsychotics (FGAs) appeared to carry a higher risk of fracture than second-generation antipsychotics (SGAs).
INTRODUCTION: The risk of fractures associated with the use of antipsychotic medications has inconsistent evidence between different drug classes. A systematic review and meta-analysis was conducted to evaluate whether there is an association between the use of antipsychotic drugs and fractures.
METHODS: Searches were conducted through the PubMed and EMBASE databases to identify observational studies that had reported a quantitative estimate of the association between use of antipsychotics and fractures. The summary risk was derived from random effects meta-analysis.
RESULTS: The search yielded 19 observational studies (n = 544,811 participants) with 80,835 fracture cases. Compared with nonuse, use of FGAs was associated with a significantly higher risk for hip fractures (OR 1.67, 95% CI, 1.45-1.93), and use of second generation antipsychotics (SGAs) was associated with an attenuated but still significant risk for hip fractures (OR 1.33, 95% CI, 1.11-1.58). The risk of fractures associated with individual classes of antipsychotic users was heterogeneous, and odds ratios ranged from 1.24 to 2.01. Chlorpromazine was associated with the highest risk (OR 2.01, 95% CI 1.43-2.83), while Risperidone was associated with the lowest risk of fracture (OR 1.24, 95% CI 0.95-1.83).
CONCLUSIONS: FGA users were at a higher risk of hip fracture than SGA users. Both FGAs and SGAs were associated with an increased risk of fractures, especially among the older population. Therefore, the benefit of the off-label use of antipsychotics in elderly patients should be weighed against any risks for fracture.

Entities:  

Keywords:  Antipsychotics; Atypical antipsychotics; Conventional antipsychotics; Femur fracture; First-generation antipsychotics; Fracture; Hip fracture; Second-generation antipsychotics

Mesh:

Substances:

Year:  2017        PMID: 28083669     DOI: 10.1007/s00198-016-3881-3

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  44 in total

1.  Quality control in systematic reviews and meta-analyses.

Authors:  M J Bown; A J Sutton
Journal:  Eur J Vasc Endovasc Surg       Date:  2010-08-21       Impact factor: 7.069

2.  Comparative safety of atypical antipsychotics and the risk of pneumonia in the elderly.

Authors:  Sandhya Mehta; Zulkarnain Pulungan; Barton T Jones; Christie Teigland
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-10-07       Impact factor: 2.890

3.  Determinants of atypical antipsychotic use among antipsychotic users in community-dwelling elderly, 1996-2004.

Authors:  Elda Jano; Michael Johnson; Hua Chen; Rajender R Aparasu
Journal:  Curr Med Res Opin       Date:  2008-01-25       Impact factor: 2.580

4.  Certain neuroleptics reduce bone mineralization in schizophrenic patients.

Authors:  T Higuchi; T Komoda; M Sugishita; J Yamazaki; M Miura; Y Sakagishi; T Yamauchi
Journal:  Neuropsychobiology       Date:  1987       Impact factor: 2.328

5.  Antipsychotic reexposure and recurrent pneumonia in schizophrenia: a nested case-control study.

Authors:  Galen Chin-Lun Hung; Hsing-Cheng Liu; Shu-Yu Yang; Chun-Hung Pan; Ya-Tang Liao; Chiao-Chicy Chen; Chian-Jue Kuo
Journal:  J Clin Psychiatry       Date:  2016-01       Impact factor: 4.384

6.  Antipsychotic-induced hyperprolactinaemia in patients with schizophrenia: considerations in relation to bone mineral density.

Authors:  B Stubbs
Journal:  J Psychiatr Ment Health Nurs       Date:  2009-11       Impact factor: 2.952

Review 7.  Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients.

Authors:  Alex J Mitchell; Davy Vancampfort; Amber De Herdt; Weiping Yu; Marc De Hert
Journal:  Schizophr Bull       Date:  2012-08-27       Impact factor: 9.306

Review 8.  Geriatric psychiatry review: differential diagnosis and treatment of the 3 D's - delirium, dementia, and depression.

Authors:  Lisa J Downing; Thomas V Caprio; Jeffrey M Lyness
Journal:  Curr Psychiatry Rep       Date:  2013-06       Impact factor: 5.285

Review 9.  A systematic review of hip fracture incidence and probability of fracture worldwide.

Authors:  J A Kanis; A Odén; E V McCloskey; H Johansson; D A Wahl; C Cooper
Journal:  Osteoporos Int       Date:  2012-03-15       Impact factor: 4.507

10.  Parameters of Calcium Metabolism Fluctuated during Initiation or Changing of Antipsychotic Drugs.

Authors:  Dragan R Milovanovic; Marijana Stanojevic Pirkovic; Snezana Zivancevic Simonovic; Milovan Matovic; Slavica Djukic Dejanovic; Slobodan M Jankovic; Dragan Ravanic; Milan Petronijevic; Dragana Ignjatovic Ristic; Violeta Mladenovic; Mirjana Jovanovic; Sandra Nikolic Labovic; Marina Pajovic; Danijela Djokovic; Dusan Petrovic; Vladimir Janjic
Journal:  Psychiatry Investig       Date:  2015-10-14       Impact factor: 2.505

View more
  10 in total

Review 1.  Adverse bone effects of medications used to treat non-skeletal disorders.

Authors:  N B Watts
Journal:  Osteoporos Int       Date:  2017-07-27       Impact factor: 4.507

2.  Antipsychotic Medication in Schizophrenic Patients is Associated with Higher Risks of Developing Bone Fractures and Refractures.

Authors:  Ching-Min Kuo; Wei-Jen Liao; Chun-Che Huang; Tsuo-Hung Lan; Ching-Heng Lin; Shun-Ping Wang; Cheng-Hung Lee; Ping-Wing Lui
Journal:  Clin Psychopharmacol Neurosci       Date:  2020-11-30       Impact factor: 2.582

Review 3.  Effects of Anorexia Nervosa on Bone Metabolism.

Authors:  Pouneh K Fazeli; Anne Klibanski
Journal:  Endocr Rev       Date:  2018-12-01       Impact factor: 19.871

Review 4.  Hyperprolactinemia and bone.

Authors:  Luigi di Filippo; Mauro Doga; Eugenia Resmini; Andrea Giustina
Journal:  Pituitary       Date:  2020-06       Impact factor: 4.107

5.  Prevalence and persistent use of psychotropic drugs in older adults receiving domiciliary care at baseline.

Authors:  Marie Turmo Lornstad; Marte Aarøen; Sverre Bergh; Jūratė Šaltytė Benth; Anne-Sofie Helvik
Journal:  BMC Geriatr       Date:  2019-04-25       Impact factor: 3.921

6.  Association of Receiving Multiple, Concurrent Fracture-Associated Drugs With Hip Fracture Risk.

Authors:  Rebecca T Emeny; Chiang-Hua Chang; Jonathan Skinner; A James O'Malley; Jeremy Smith; Gouri Chakraborti; Clifford J Rosen; Nancy E Morden
Journal:  JAMA Netw Open       Date:  2019-11-01

7.  Falls and Fractures in Patients with Parkinson's Disease-Related Psychosis Treated with Pimavanserin vs Atypical Antipsychotics: A Cohort Study.

Authors:  J Bradley Layton; Joan Forns; Mary Ellen Turner; Colleen Dempsey; Jennifer L Bartsch; Mary S Anthony; Heather E Danysh; Mary E Ritchey; George Demos
Journal:  Drugs Real World Outcomes       Date:  2021-10-30

8.  Exposure to risperidone versus other antipsychotics and risk of osteoporosis-related fractures: a population-based study.

Authors:  E Clapham; R Bodén; J Reutfors; T Svensson; D Ramcharran; H Qiu; H Kieler; S Bahmanyar
Journal:  Acta Psychiatr Scand       Date:  2019-10-11       Impact factor: 6.392

Review 9.  The Effects of Osteoporotic and Non-osteoporotic Medications on Fracture Risk and Bone Mineral Density.

Authors:  Anna C van der Burgh; Catherine E de Keyser; M Carola Zillikens; Bruno H Stricker
Journal:  Drugs       Date:  2021-11-01       Impact factor: 9.546

10.  Association between Anti-Psychotic Drugs Use and Hip Fractures in Patients with Dementia: A Nationwide Population-Based Study.

Authors:  Chia-Hung Tang; Yi-Chen Lai; Yi-Chen Chen; Shun-Min Chang; Yu-Han Chen; Jung-Yu Liao; Yi-Chi Wang; Chung-Han Ho; Ping-Jen Chen
Journal:  Int J Environ Res Public Health       Date:  2021-07-31       Impact factor: 3.390

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.